GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will be participating in two upcoming scientific conferences.
- Alliance for Regenerative Medicine's 6th Annual Regenerative Medicine & Advanced Therapies State of the Industry Briefing – San Francisco, Calif. (January 11, 2016)
AGTC President and CEO Sue Washer will participate in a panel discussion entitled, “The 2016 Sector Forecast: Upcoming Clinical Data Events,” taking place from 8:20 am – 9:05 am. The session will feature senior executives from leading companies in the regenerative medicine and advanced therapies sector for a forward-looking discussion of expected clinical data events in 2016 and beyond. Panelists will address key issues related to continuing momentum in the sector as well as unique strategies and partnerships that will be required for success going forward.
- Phacilitate Cell & Gene Therapy World – Washington, D.C. (January 25-27, 2016)
- Ms. Washer will deliver a keynote address and moderate an investor panel during the opening plenary entitled, “Cell & gene therapy ‘State of the Industry’” on January 25 th from 11:25 am – 12:05 pm.
- Ms. Washer will also present on behalf of Southeast BIO (SEBIO) and BioFlorida at the newly established Regional Pavilion at Washington Leaders Forum in partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) on January 26 th from 2:00 pm – 2:15 pm. She is the Chair of SEBIO and a member of the BioFlorida Executive Committee.
- Stephen Potter, AGTC’s Chief Business Officer, will participate in a panel discussion entitled, “Defining the prospects for – and current resilience of – the cell & gene therapy field in investors’ eyes” on January 26 th from 9:05 am – 9:55 am.
- Ms. Washer will also join international leaders from across the biotech industry as a member of the Phacilitate advisory board, beginning January 2016.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC’s product pipeline includes five ophthalmology development programs across four named targets [x-linked retinoschisis (XLRS), x-linked retinitis pigmentosa (XLRP), achromatopsia, and wet age-related macular degeneration], one non-ophthalmology program (alpha-1 antitrypsin deficiency) and proof-of-concept data in multiple additional indications. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.
Forward Looking Statements
Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors, which include, but are not limited to, the following: no gene therapy products have been approved in the United States and AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate; AGTC relies on third parties to conduct, supervise and monitor its clinical trials and to conduct certain aspects of its product manufacturing and protocol development; and increased regulatory scrutiny of gene therapy and genetic research could damage public perception of AGTC’s product candidates or adversely affect AGTC’s ability to conduct its business. Additional factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading “Item 1A—Risk Factors" in AGTC's Annual Report on Form 10-K for the fiscal year ended June 30, 2015, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, AGTC assumes no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
IR/PR CONTACTS: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 dcarey@lazarpartners.com or dlewis@lazarpartners.com Corporate Contacts: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 lbullock@agtc.com Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 spotter@agtc.com
